Crinetics Pharmaceuticals (CRNX) Cash from Operations Growth (1y) (2018 - 2026)
Crinetics Pharmaceuticals (CRNX) Cash from Operations Growth (1y) (2018 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,320.50 Bn | 66,320.21 Bn | - | 7.14% |
| 2 | Nanobiotix | 1,933.82 Bn | 1,933.76 Bn | - | - |
| 3 | Akari Therapeutics | 1,022.34 Bn | 1,022.34 Bn | - | - |
| 4 | BeOne Medicines | 472.93 Bn | 468.14 Bn | 1.35 Bn | 356.73% |
| 5 | Vertex Pharmaceuticals | 122.22 Bn | 114.98 Bn | 2.59 Bn | 74.39% |
| 6 | Regeneron Pharmaceuticals | 69.96 Bn | 61.21 Bn | 3.31 Bn | 3.23% |
| 7 | Belite Bio | 62.66 Bn | 62.66 Bn | - | - |
| 8 | Argenx Se | 56.07 Bn | 50.89 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.60 Bn | 34.59 Bn | 959.66 Mn | 158.60% |
| 10 | Crinetics Pharmaceuticals | 8.73 Bn | 7.44 Bn | 10.53 Mn | -40.98% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -40.98% |
| Dec 31, 2025 | -38.93% |
| Sep 30, 2025 | -76.24% |
| Jun 30, 2025 | -80.19% |
| Mar 31, 2025 | -67.35% |
| Dec 31, 2024 | -63.88% |
| Sep 30, 2024 | -51.97% |
| Jun 30, 2024 | -4.17% |
| Mar 31, 2024 | -29.81% |
| Dec 31, 2023 | -15.90% |
| Sep 30, 2023 | -7.43% |
| Jun 30, 2023 | -63.48% |
| Mar 31, 2023 | -200.66% |
| Dec 31, 2022 | -53.75% |
| Sep 30, 2022 | -49.88% |
| Jun 30, 2022 | -40.24% |
| Mar 31, 2022 | 32.51% |
| Dec 31, 2021 | -43.68% |
| Sep 30, 2021 | -42.60% |
| Jun 30, 2021 | -25.82% |